ISD-Immunotech Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Out of Business

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Out of Business

ISD-Immunotech General Information

Description

Developer of sting modulators designed to treat severe systemic lupus erythematosus or lupus by targeting the sting pathway. The company offers therapy that works by dampening the action of an intracellular protein called stimulator of interferon genes, and when triggered, it ramps up the production of inflammatory proteins called interferons and cytokines, which boost the immune system, helping patients to fight against pathogen invaders like bacteria and viruses.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Stærmosevej 12
  • East
  • 7120 Vejle
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Therapeutic Devices
Corporate Office
  • Stærmosevej 12
  • East
  • 7120 Vejle
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ISD-Immunotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 01-Mar-2023 Completed Out of Business
6. Seed Round 13-Oct-2021 Completed Generating Revenue
5. Debt - General Completed Startup
4. Seed Round 01-Jul-2020 Completed Startup
3. Seed Round 19-Apr-2018 Completed Startup
2. Accelerator/Incubator 01-Jan-2017 $44.8K $44.8K Completed Startup
1. University Spin-Out 01-Jan-2007 Completed Startup
To view ISD-Immunotech’s complete valuation and funding history, request access »

ISD-Immunotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 14,222 $11.03 $11.03 1x $11.03 6.32%
Ordinary 3,000 $16.51 $16.51 1x $16.51 1.33%
To view ISD-Immunotech’s complete cap table history, request access »

ISD-Immunotech Patents

ISD-Immunotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2983706-A2 Use of immune suppressive domains as medicaments Active 10-Apr-2013
EP-2983706-B1 Use of immune suppressive domains as medicaments Active 10-Apr-2013
EP-3906931-A2 Use of immune suppressive domains as medicaments Inactive 10-Apr-2013
EP-3906931-A3 Use of immune suppressive domains as medicaments Inactive 10-Apr-2013
US-11484567-B2 Use of immune suppressive domains as medicaments Active 10-Apr-2013 A61K39/0008
To view ISD-Immunotech’s complete patent history, request access »

ISD-Immunotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ISD-Immunotech FAQs

  • When was ISD-Immunotech founded?

    ISD-Immunotech was founded in 2007.

  • Where is ISD-Immunotech headquartered?

    ISD-Immunotech is headquartered in Vejle, Denmark.

  • What is the size of ISD-Immunotech?

    ISD-Immunotech has 5 total employees.

  • What industry is ISD-Immunotech in?

    ISD-Immunotech’s primary industry is Drug Discovery.

  • Is ISD-Immunotech a private or public company?

    ISD-Immunotech is a Private company.

  • What is ISD-Immunotech’s current revenue?

    The current revenue for ISD-Immunotech is .

  • How much funding has ISD-Immunotech raised over time?

    ISD-Immunotech has raised $2.3M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process